相关实验视频
Updated: May 12, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
155
针对PD-1的翻译后修改,以改善癌症免疫治疗
Jie Shi1,2, Chuan He1,2, Li Chen3
1Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, Hubei, China.
Cell insight
|May 8, 2025
概括
编程细胞死亡蛋白1 (PD-1) 的翻译后修改 (PTM) 是癌症免疫逃避的关键. 针对这些PD-1 PTM提供了有效的癌症免疫治疗的新策略.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 编程细胞死亡蛋白1 (PD-1) 是一种免疫检查点受体,通过PD-L1相互作用对免疫抑制至关重要.
- 瘤利用PD-1/PD-L1轴逃避免疫监测,导致免疫检查点抑制剂的发展.
- 目前PD-1/PD-L1封锁有效性的局限性源于对基础监管机制的不完全理解.
研究的目的:
- 审查最近关于编程细胞死亡蛋白1 (PD-1) 后翻译性修饰 (PTMs) 的作用的发现.
- 探索针对PD-1 PTM的新兴治疗策略,以加强癌症免疫治疗.
- 为推进组合癌症免疫疗法提供机制性见解.
主要方法:
- 文献综述,重点关注最近的研究成果.
- 对研究PD-1后翻译性修饰 (PTMs) 的分析,如泛化,UFMylation,酸化,棕化和糖化.
- 检查针对PD-1 PTMs的治疗策略的临床前和临床数据.
主要成果:
- 各种PTM关键调节PD-1的稳定性,局部化和相互作用.
- PD-1 PTMs的失调有助于免疫逃避和抗癌疗法的抵抗.
- 用小分子或抗体向PD-1 PTM在临床前模型和临床试验中显示出有希望的结果.
结论:
- 了解PD-1 PTM对于克服当前癌症免疫疗法的局限性至关重要.
- 调节PD-1 PTMs代表了增强抗瘤免疫力的有希望的治疗途径.
- 整合PD-1 PTM的知识可以促进更有效的组合癌症免疫疗法的合理设计.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
401
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
401
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K

